The medical community is abuzz following the publication of late-stage clinical trial results for a revolutionary new mRNA-based cancer vaccine. Jointly developed by leading European and American pharmaceutical researchers, the personalized therapy trains the patient’s own immune system to identify and destroy specific cancer cells without the debilitating side effects of traditional chemotherapy. The Phase 3 trials, focused primarily on advanced melanoma and certain lung cancers, have reported an unprecedented 85% sustained remission rate among participants. Regulatory agencies are fast-tracking the approval process, meaning this life-saving, highly targeted treatment could be available to oncology wards globally within the next twelve months.